List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5080570/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature, 2022, 601, 110-117.	27.8	280
2	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	12.6	91
3	Vaccine efficacy and immune interference: co-administering COVID-19 and influenza vaccines. Lancet Respiratory Medicine,the, 2022, 10, 125-126.	10.7	2
4	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	8.1	100
5	Rapid synchronous type 1 IFN and virus-specific TÂcell responses characterize first wave non-severe SARS-CoV-2 infections. Cell Reports Medicine, 2022, 3, 100557.	6.5	36
6	HLAâ€DR polymorphism in SARSâ€CoVâ€2 infection and susceptibility to symptomatic COVIDâ€19. Immunology, 2022, 166, 68-77.	4.4	18
7	COVID-19 vaccination: The road ahead. Science, 2022, 375, 1127-1132.	12.6	134
8	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
9	Immune boosting by B.1.1.529 <b>(</b> Omicron) depends on previous SARS-CoV-2 exposure. Science, 2022, 377, .	12.6	241
10	Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respiratory Medicine,the, 2022, 10, 840-850.	10.7	52
11	Decoding the unknowns in long covid. BMJ, The, 2021, 372, n132.	6.0	44
12	Immunity to SARS-CoV-2 variants of concern. Science, 2021, 371, 1103-1104.	12.6	169
13	Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet, The, 2021, 397, 1057-1058.	13.7	360
14	Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. Journal of Infection, 2021, 82, 399-406.	3.3	106
15	Risk of SARS-CoV-2 reinfection after natural infection. Lancet, The, 2021, 397, 1161-1163.	13.7	53
16	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARSâ€'CoV-2 infection. EBioMedicine, 2021, 65, 103259.	6.1	61
17	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372, 1418-1423.	12.6	286
18	SARS-CoV-2 variants: Subversion of antibody response and predicted impact on TÂcell recognition. Cell Reports Medicine, 2021, 2, 100286.	6.5	18

#	Article	IF	CITATIONS
19	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines, 2021, 6, 74.	6.0	198
20	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy , 2021, 9, e003311.		66
21	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517.	7.3	52
22	Waning immunity to SARS-CoV-2: implications for vaccine booster strategies. Lancet Respiratory Medicine,the, 2021, 9, 1356-1358.	10.7	35
23	The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?. Nature Reviews Immunology, 2021, 21, 762-768.	22.7	80
24	Covid-19 caseload in the UKâ $\in$ "assessments and mitigations. BMJ, The, 2021, 375, n2843.	6.0	2
25	SARS-Cov-2 immune waning and reinfection in care-home settings. The Lancet Healthy Longevity, 2021, 2, e776-e777.	4.6	0
26	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811.	12.6	10
27	BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis. Frontiers in Immunology, 2021, 12, 767359.	4.8	6
28	SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Science Immunology, 2020, 5, .	11.9	240
29	Multiplexed gene expression analysis of HLA class II-associated podoconiosis implicates chronic immune activation in its pathogenesis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 926-936.	1.8	4
30	Strong CD4 T Cell Responses to Zika Virus Antigens in a Cohort of Dengue Virus Immune Mothers of Congenital Zika Virus Syndrome Infants. Frontiers in Immunology, 2020, 11, 185.	4.8	12
31	What policy makers need to know about COVID-19 protective immunity. Lancet, The, 2020, 395, 1527-1529.	13.7	188
32	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Science Immunology, 2020, 5, .	11.9	172
33	Proteome-Wide Zika Virus CD4 T Cell Epitope and HLA Restriction Determination. ImmunoHorizons, 2020, 4, 444-453.	1.8	8
34	Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. ELife, 2020, 9, .	6.0	26
35	Antibiotic therapy and outcome from immune-checkpoint inhibitors. , 2019, 7, 287.		77
36	ER-localized Hrd1 ubiquitinates and inactivates Usp15 to promote TLR4-induced inflammation during bacterial infection. Nature Microbiology, 2019, 4, 2331-2346.	13.3	39

#	Article	IF	CITATIONS
37	Human NK cell receptor KIR2DS4 detects a conserved bacterial epitope presented by HLA-C. Proceedings of the United States of America, 2019, 116, 12964-12973.	7.1	59
38	Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut, 2019, 68, 1430-1438.	12.1	235
39	Bioluminescent Reporting of In Vivo IFN-γ Immune Responses during Infection and Autoimmunity. Journal of Immunology, 2019, 202, 2502-2510.	0.8	8
40	Immune Control of Burkholderia pseudomallei––Common, High-Frequency T-Cell Responses to a Broad Repertoire of Immunoprevalent Epitopes. Frontiers in Immunology, 2018, 9, 484.	4.8	15
41	Lung Defense through IL-8 Carries a Cost of Chronic Lung Remodeling and Impaired Function. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 557-571.	2.9	48
42	Infection with Burkholderia pseudomallei – immune correlates of survival in acute melioidosis. Scientific Reports, 2017, 7, 12143.	3.3	42
43	Guillain-Barré syndrome and arboviral infection in Brazil. Lancet Infectious Diseases, The, 2017, 17, 693-694.	9.1	13
44	Canonical and Cross-reactive Binding of NK Cell Inhibitory Receptors to HLA-C Allotypes Is Dictated by Peptides Bound to HLA-C. Frontiers in Immunology, 2017, 8, 193.	4.8	40
45	CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal Factor. Frontiers in Microbiology, 2016, 6, 1506.	3.5	11
46	BIITE: A Tool to Determine HLA Class II Epitopes from T Cell ELISpot Data. PLoS Computational Biology, 2016, 12, e1004796.	3.2	4
47	Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 523-554.	22.4	84
48	KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells. European Journal of Immunology, 2016, 46, 185-191.	2.9	23
49	Natural cutaneous anthrax infection, but not vaccination, induces a CD4+ T cell response involving diverse cytokines. Cell and Bioscience, 2015, 5, 20.	4.8	7
50	MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity. BMC Neurology, 2015, 15, 72.	1.8	9
51	Replace 'pathogens' with 'perceptogens'. Nature, 2015, 518, 35-35.	27.8	4
52	Autoantigen cross-reactive environmental antigen can trigger multiple sclerosis-like disease. Journal of Neuroinflammation, 2015, 12, 91.	7.2	3
53	Chronic Infection by Mucoid <i>Pseudomonas aeruginosa</i> Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1250-1264.	5.6	27
54	T Cell Immunity to the Alkyl Hydroperoxide Reductase of <i>Burkholderia pseudomallei</i> : A Correlate of Disease Outcome in Acute Melioidosis. Journal of Immunology, 2015, 194, 4814-4824.	0.8	44

#	Article	IF	CITATIONS
55	Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax, 2014, 69, 335-345.	5.6	13
56	Anthrax Lethal Factor as an Immune Target in Humans and Transgenic Mice and the Impact of HLA Polymorphism on CD4+ T Cell Immunity. PLoS Pathogens, 2014, 10, e1004085.	4.7	18
57	CD4+ T Cell Epitopes of FliC Conserved between Strains of <i>Burkholderia</i> : Implications for Vaccines against Melioidosis and Cepacia Complex in Cystic Fibrosis. Journal of Immunology, 2014, 193, 6041-6049.	0.8	27
58	The serodominant secreted effector protein of <i>Salmonella</i> , SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse <scp>HLA</scp> class <scp>II</scp> alleles. Immunology, 2014, 143, 438-446.	4.4	32
59	Elongated TCR alpha chain CDR3 favors an altered CD4 cytokine profile. BMC Biology, 2014, 12, 32.	3.8	4
60	Injectional anthrax infection due to heroin use induces strong immunological memory. Journal of Infection, 2014, 68, 200-203.	3.3	10
61	Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response. Acta Neuropathologica, 2013, 126, 501-515.	7.7	32
62	Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis. Clinical and Experimental Immunology, 2013, 171, 117-123.	2.6	53
63	Increased <scp>HLA</scp> â€E expression in white matter lesions in multiple sclerosis. Immunology, 2012, 137, 317-325.	4.4	24
64	Immune regulation in idiopathic bronchiectasis. Annals of the New York Academy of Sciences, 2012, 1272, 68-72.	3.8	8
65	Innate Immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1). Journal of Neuroinflammation, 2012, 9, 1.	7.2	147
66	A role of cellular prion protein in programming T ell cytokine responses in disease. FASEB Journal, 2009, 23, 1672-1684.	0.5	22
67	Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression. Journal of Experimental Medicine, 2009, 206, 1535-1547.	8.5	192
68	Natural killer T cells in bronchial biopsies from human allergen challenge model of allergic asthma. Journal of Allergy and Clinical Immunology, 2009, 124, 860-862.	2.9	37
69	Human leucocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity. Clinical and Experimental Immunology, 2008, 152, 95-101.	2.6	35
70	Pulmonary Infection with <i>Cryptococcus neoformans</i> in the Face of Underlying Sarcoidosis. Respiration, 2007, 74, 462-466.	2.6	12
71	Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clinical and Experimental Immunology, 2007, 149, 1-8.	2.6	142
72	Models of sarcoidosis. Drug Discovery Today: Disease Models, 2006, 3, 21-25.	1.2	7

#	Article	IF	CITATIONS
73	IFN? and CXCR-1 gene polymorphisms in idiopathic bronchiectasis. Tissue Antigens, 2006, 68, 325-330.	1.0	21
74	HLA-C and Killer Cell Immunoglobulin-like Receptor Genes in Idiopathic Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 327-333.	5.6	67
75	Infectious lung complications in patients with HIV/AIDS. Current Opinion in Internal Medicine, 2005, 4, 400-404.	1.5	23
76	Stat4-null non-obese diabetic mice: protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread. International Immunology, 2005, 17, 1157-1165.	4.0	26
77	High Incidence of Spontaneous Disease in an HLA-DR15 and TCR Transgenic Multiple Sclerosis Model. Journal of Immunology, 2005, 174, 1938-1946.	0.8	74
78	Asthma: new developments in cytokine regulation. Clinical and Experimental Immunology, 2004, 136, 13-14.	2.6	19
79	Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. European Journal of Immunology, 2004, 34, 1839-1848.	2.9	52
80	Models of multiple sclerosis. Drug Discovery Today: Disease Models, 2004, 1, 405-410.	1.2	7
81	Reciprocal conditioning: T cells as regulators of dendritic cell function. Immunology, 2003, 109, 473-475.	4.4	1
82	Pulmonary defences to acute respiratory infection. British Medical Bulletin, 2002, 61, 1-12.	6.9	81
83	CD4 T Cells Selected by Antigen Under Th2 Polarizing Conditions Favor an Elongated TCRα Chain Complementarity-Determining Region 3. Journal of Immunology, 2002, 168, 1018-1027.	0.8	17
84	Is selection for TCR affinity a factor in cytokine polarization?. Trends in Immunology, 2002, 23, 526-529.	6.8	58